Physical Activity in Children With Wolff-Parkinson-White Syndrome

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Wolff-Parkinson-White Syndrome Clinical Trial

Official title:
Physical Activity Level and Determinants in Children With Wolff-Parkinson-White Syndrome

Status Recruiting

Clinical Trial Summary

The aim of this study was to investigate the level of physical activity and its determinants in children with WPW.

n/a

NCT number	NCT06349109
Study type	Observational
Source	Karamanoglu Mehmetbey University
Contact	Haluk Tekerlek, PhD
Phone	+90-5355915009
Email	haluktekerlek@gmail.com
Status	Recruiting
Phase
Start date	March 1, 2024
Completion date	May 1, 2025

See also
Status	Clinical Trial	Phase
Completed	`NCT00251121` - Routine Mini-invasive Electrophysiology Study for Patients Feeling Tachycardia, With a Negative Holter ECG	N/A
Not yet recruiting	`NCT04106622` - Accessory Pathway Antegrade Effective Refractory Period Among WPW Patients: the Risk in Relation to the Location
Terminated	`NCT00873470` - Wolff-Parkinson-White Syndrome Anterograde Refractory Period of Accessory Duct	N/A
Completed	`NCT03301935` - Risk Assessment in Patients With Symptomatic- and Asymptomatic Preexcitation
Terminated	`NCT03207373` - Stress ECG Test for the Evaluation of the Risk of Sudden Cardiac Death in a Paediatric Cohort With WPW Pattern	N/A